DIANTHUS THERAPEUTICS INC (DNTH) Stock News

USA - NASDAQ:DNTH - US2528281080 - Common Stock

35.65 USD

-0.35 (-0.97%)

Last: 10/17/2025, 8:07:02 PM

35.8 USD

+0.15 (+0.42%)

Pre-Market: 10/20/2025, 8:44:35 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DNTH Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

4 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

18 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

18 days ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting

a month ago - By: Benzinga - Mentions: APP ADBE AI GM ...

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday

a month ago - By: Benzinga - Mentions: CNTA KRRO

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

2 months ago - By: The Motley Fool

Dianthus (DNTH) Q2 Loss Widens 80%

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering

a month ago - By: Investor's Business Daily - Mentions: ARGX AZN SNY

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

a month ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

2 months ago - By: Toi Management, LLC - Mentions: TOI

The Oncology Institute Announces Changes to Board of Directors

2 months ago - By: Zacks Investment Research - Mentions: CVAC

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

2 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

2 months ago - By: Zacks Investment Research - Mentions: INO

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

2 months ago - By: Zacks Investment Research - Mentions: SEER

Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Yahoo Finance

Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside

5 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

5 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference

5 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

5 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

5 months ago - By: Zacks Investment Research - Mentions: VTGN

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates

5 months ago - By: Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results